Treatment of medulloblastoma with a modified measles virus

Adam W. Studebaker, Cole R. Kreofsky, Christopher R. Pierson, Stephen J Russell, Evanthia Galanis, Corey Raffel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. The objective of this study was to test the efficacy of measles virus in treating medulloblastoma. To determine whether medulloblastoma cells are susceptible, 5 different human medulloblastoma cell lines were analyzed for the expression of the measles virus receptor CD46. Fluorescence-activated cell-sorting analysis confirmed expression of CD46 on all cell lines tested, with UW288-1 having the most prominent expression andD283med displaying the lowest expression. CD46 expression was also demonstrated, using immunohistochemistry, in 13 of 13 medulloblastoma tissue specimens. All 5 medulloblastoma cell lines were examined for their susceptibility to measles virus killing in vitro. A measles virus containing the green fluorescent protein (GFP) gene as a marker for infection (MVGFP) was used. All cell lines exhibited significant killing when infected withMV-GFP, all formed syncytia with infection, all showed fluorescence, and all allowed viral replicaton after infection. In an intracerebral murine xenograft model, a statistically significant increase in survival was seen in animals treated with the active measles virus compared with those treated with inactivated virus. These data demonstrate that medulloblastoma is susceptible to measles virus killing and that the virus may have a role in treating this tumor in the clinical setting.

Original languageEnglish (US)
Pages (from-to)1034-1042
Number of pages9
JournalNeuro-Oncology
Volume12
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Measles virus
Medulloblastoma
Cell Line
Green Fluorescent Proteins
Therapeutics
Infection
Oncolytic Viruses
Viruses
Virus Receptors
Giant Cells
Heterografts
Brain Neoplasms
Neoplasms
Flow Cytometry
Fluorescence
Immunohistochemistry
Morbidity
Survival
Genes

Keywords

  • Bioluminescence
  • Measles virus
  • Medulloblastoma
  • Oncolytic virus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Studebaker, A. W., Kreofsky, C. R., Pierson, C. R., Russell, S. J., Galanis, E., & Raffel, C. (2010). Treatment of medulloblastoma with a modified measles virus. Neuro-Oncology, 12(10), 1034-1042. https://doi.org/10.1093/neuonc/noq057

Treatment of medulloblastoma with a modified measles virus. / Studebaker, Adam W.; Kreofsky, Cole R.; Pierson, Christopher R.; Russell, Stephen J; Galanis, Evanthia; Raffel, Corey.

In: Neuro-Oncology, Vol. 12, No. 10, 10.2010, p. 1034-1042.

Research output: Contribution to journalArticle

Studebaker, AW, Kreofsky, CR, Pierson, CR, Russell, SJ, Galanis, E & Raffel, C 2010, 'Treatment of medulloblastoma with a modified measles virus', Neuro-Oncology, vol. 12, no. 10, pp. 1034-1042. https://doi.org/10.1093/neuonc/noq057
Studebaker, Adam W. ; Kreofsky, Cole R. ; Pierson, Christopher R. ; Russell, Stephen J ; Galanis, Evanthia ; Raffel, Corey. / Treatment of medulloblastoma with a modified measles virus. In: Neuro-Oncology. 2010 ; Vol. 12, No. 10. pp. 1034-1042.
@article{1ce7612aa6f84065b773a8f453d9a820,
title = "Treatment of medulloblastoma with a modified measles virus",
abstract = "Although treatment of medulloblastoma has improved, at least 30{\%} of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. The objective of this study was to test the efficacy of measles virus in treating medulloblastoma. To determine whether medulloblastoma cells are susceptible, 5 different human medulloblastoma cell lines were analyzed for the expression of the measles virus receptor CD46. Fluorescence-activated cell-sorting analysis confirmed expression of CD46 on all cell lines tested, with UW288-1 having the most prominent expression andD283med displaying the lowest expression. CD46 expression was also demonstrated, using immunohistochemistry, in 13 of 13 medulloblastoma tissue specimens. All 5 medulloblastoma cell lines were examined for their susceptibility to measles virus killing in vitro. A measles virus containing the green fluorescent protein (GFP) gene as a marker for infection (MVGFP) was used. All cell lines exhibited significant killing when infected withMV-GFP, all formed syncytia with infection, all showed fluorescence, and all allowed viral replicaton after infection. In an intracerebral murine xenograft model, a statistically significant increase in survival was seen in animals treated with the active measles virus compared with those treated with inactivated virus. These data demonstrate that medulloblastoma is susceptible to measles virus killing and that the virus may have a role in treating this tumor in the clinical setting.",
keywords = "Bioluminescence, Measles virus, Medulloblastoma, Oncolytic virus",
author = "Studebaker, {Adam W.} and Kreofsky, {Cole R.} and Pierson, {Christopher R.} and Russell, {Stephen J} and Evanthia Galanis and Corey Raffel",
year = "2010",
month = "10",
doi = "10.1093/neuonc/noq057",
language = "English (US)",
volume = "12",
pages = "1034--1042",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Treatment of medulloblastoma with a modified measles virus

AU - Studebaker, Adam W.

AU - Kreofsky, Cole R.

AU - Pierson, Christopher R.

AU - Russell, Stephen J

AU - Galanis, Evanthia

AU - Raffel, Corey

PY - 2010/10

Y1 - 2010/10

N2 - Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. The objective of this study was to test the efficacy of measles virus in treating medulloblastoma. To determine whether medulloblastoma cells are susceptible, 5 different human medulloblastoma cell lines were analyzed for the expression of the measles virus receptor CD46. Fluorescence-activated cell-sorting analysis confirmed expression of CD46 on all cell lines tested, with UW288-1 having the most prominent expression andD283med displaying the lowest expression. CD46 expression was also demonstrated, using immunohistochemistry, in 13 of 13 medulloblastoma tissue specimens. All 5 medulloblastoma cell lines were examined for their susceptibility to measles virus killing in vitro. A measles virus containing the green fluorescent protein (GFP) gene as a marker for infection (MVGFP) was used. All cell lines exhibited significant killing when infected withMV-GFP, all formed syncytia with infection, all showed fluorescence, and all allowed viral replicaton after infection. In an intracerebral murine xenograft model, a statistically significant increase in survival was seen in animals treated with the active measles virus compared with those treated with inactivated virus. These data demonstrate that medulloblastoma is susceptible to measles virus killing and that the virus may have a role in treating this tumor in the clinical setting.

AB - Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. The objective of this study was to test the efficacy of measles virus in treating medulloblastoma. To determine whether medulloblastoma cells are susceptible, 5 different human medulloblastoma cell lines were analyzed for the expression of the measles virus receptor CD46. Fluorescence-activated cell-sorting analysis confirmed expression of CD46 on all cell lines tested, with UW288-1 having the most prominent expression andD283med displaying the lowest expression. CD46 expression was also demonstrated, using immunohistochemistry, in 13 of 13 medulloblastoma tissue specimens. All 5 medulloblastoma cell lines were examined for their susceptibility to measles virus killing in vitro. A measles virus containing the green fluorescent protein (GFP) gene as a marker for infection (MVGFP) was used. All cell lines exhibited significant killing when infected withMV-GFP, all formed syncytia with infection, all showed fluorescence, and all allowed viral replicaton after infection. In an intracerebral murine xenograft model, a statistically significant increase in survival was seen in animals treated with the active measles virus compared with those treated with inactivated virus. These data demonstrate that medulloblastoma is susceptible to measles virus killing and that the virus may have a role in treating this tumor in the clinical setting.

KW - Bioluminescence

KW - Measles virus

KW - Medulloblastoma

KW - Oncolytic virus

UR - http://www.scopus.com/inward/record.url?scp=77958461551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958461551&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq057

DO - 10.1093/neuonc/noq057

M3 - Article

VL - 12

SP - 1034

EP - 1042

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 10

ER -